Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm
NCT07396155
Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial
Sponsor: Dr. Sardjito General Hospital, Yogyakarta, Indonesia
Conditions
Diabetic Nephropathy Type 2
Interventions
Umbilical Cord Mesenchymal Stem Cells
Updated 1 time since 2026 Last updated: Feb 3, 2026 Started: Jul 1, 2026 Primary completion: Jul 31, 2027 Completion: Oct 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1/PHASE2 trial investigates Diabetic Nephropathy Type 2 and is currently actively recruiting participants. Dr. Sardjito General Hospital, Yogyakarta, Indonesia leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Recruiting — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Dr. Sardjito General Hospital, Yogyakarta, Indonesia
- PT. Prodia Stem Cell Indonesia
Data source: PT. Prodia Stem Cell Indonesia
For direct contact, visit the study record on ClinicalTrials.gov .